reflect updat definit core financi measur exclud
intang asset amort charg impair except
is-rel intang
summar promis roxadustat data present last week data
expect ye underpin file separ took anoth look azn
model advanc result ep estim lower forecast
intact thereaft estim chang mix azn continu look pois deliv
strong ep growth
roxadustat second-gener oral small molecul inhibitor hypoxia-induc factor
hif polyl hydroxylas ph current roxadustat phase anemia due chronic
renal failur dialysis-depend dialysis-independ popul well
anemia due cancer therapi current standard care chronic kidney diseas ckd
erythropoiesi stimul agent esa howev safeti concern limit use
trial conduct china
phase trial patient stage ckd random
receiv roxadustat placebo treatment follow
open-label cours elig criteria includ patient receiv
esa least week prior random mean recent
hemoglobin measur greater than/equ greater g/dl
subject receiv oral roxadustat time per week use weight-bas start dose
mg less kg mg greater equal kg roxadustat
titrat everi week base chang hemoglobin level primari endpoint
mean hemoglobin chang baselin week secondari endpoint includ mean
chang iron biomark total cholesterol averag week chang
hepcidin trial size achiev least power demonstr signific
mean differ g/dl /- g/dl signific level
full popul patient receiv roxadustat patient receiv placebo
due discontinu patient roxadustat placebo evalu
initi treatment period roxadustat patient experienc greater mean
chang hemoglobin averag week /- g/dl vs placebo /-
g/dl roxadustat patient achiev hemoglobin respons
increas greater equal g/dl baselin compar placebo
averag week roxadustat patient achiev mean
hemoglobin greater equal g/dl compar placebo
addit roxadustat patient requir rescu therapi versu placebo
pleas see page report import disclosur
azn promis pipelin particip mani larg high growth market
stock move line outlook offset uncertainti
relat data key diabet respiratori franchis ep prospect particularli
year price-to-earnings multipl steep azn improv await greater clariti
outlook and/or attract entri point
imfinzi imfinzi tremelimumab data/
regulatori decis sever tumors/
uptak new product notabl
imfinzi lynparza fasenra
improv diabet respiratori
new product unabl sustain share
astrazeneca biopharmaceut compani domicil group
acquir medimmun biolog vaccin busi base key product
area cardiovascular respiratori oncolog
azn
azn
subsequ open-label period patient
initi treat roxadustat demonstr overal hemoglobin chang
baselin g/dl week patient initi treat
placebo switch roxadustat demonstr
hemoglobin chang baselin initi roxadustat /-
g/dl result show robust erythropoiesi roxadustat
arm serum iron remain stabl oral iron supplement
azn
roxadustat demonstr favor safeti profil dialysis-independ
ckd patient also show signific efficaci correct anemia
initi cross-ov treatment roxadustat dialysis-
independ ckd popul four addit global pivot phase trial
pursu evalu roxadustat long-term hemoglobin respons
major advers cardiovascular event primari outcom posit
data announc phase alp studi statist signific
hemoglobin respons chang hemoglobin baselin
averag week result present upcom
medic meet howev first trial conduct europ
middl east africa support file europ
phase trial patient end-stag renal
diseas esrd random receiv oral roxadustat
receiv hemodialysi periton dialysi least week
stabl dose epoetin-alfa least week whose mean
most-rec hemoglobin valu g/dl roxadustat dose
titrat everi week hemoglobin target g/dl base
chang hemoglobin level oral iron allow primari
endpoint mean hemoglobin chang baselin averag week
non-inferior superior test would perform use
full popul patient receiv roxadustat patient
receiv placebo due discontinu patient roxadustat
placebo evalu compar baselin averag week
roxadustat treatment show numer greater mean chang
hemoglobin /- g/dl vs epoetin-alfa /- g/dl roxadustat
demonstr non-inferior also superior epoetin-alfa per-
protocol popul howev roxadustat demonstr non-
inferior superior full popul proport subject
mean hemoglobin g/dl roxadustat
epoetin-alfa treatment differ compar subgroup
elev crp level roxadustat demonstr greater chang
azn
azn
compar phase trial roxadustat demonstr non-inferior
well superior mainten anemia correct week
improv hemoglobin level across subgroup inflamm
even high-dos epoetin-alfa could improv inflamm subgroup
level non-inflamm subgroup phase trial
pursu one consid pivot pivot phase
pyrene initi novemb primari complet
juli trial end juli studi evalu safeti
efficaci roxadustat vs erythropoiesi stimul agent epoetin alfa
darbepoetin alfa co-primari endpoint hemoglobin chang
baselin averag hb week regardless rescu therapi
 hemoglobin chang baselin averag hb week
without receiv rescu therapi eu azn expect
present result
ahead result took anoth look azn model ep
estim reduc ep forecast
intact vs consensu ep estim
reduc still impli growth vs consensu
thereaft estim rais amount rang
mainli attribut higher roxadustat sale
ep estim impli ep growth
compani data cowen compani estim
productexternalizationtotalgross otherop pretaxtaxnet ep y/ysharessalesrevenu chg report mm sl mm slsop inc dil divestitur interest divestitur interest retain payment diabet product impact core ep sg ar cowen
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
 launch lc ex fx nexium gener major marketsnexium estab expir japan japan canada australia new zealandnexium emerg product pressur marketlosec lc ex fx losec estab canada australia new zealandlosec emerg patent mani marketsoth lc ex fx estab canada australia new zealandoth emerg patent mani oral peripherally-act opioid antag opioid-induc constip co-commerci daiichi launch nordic countri eu aspirin combo gener pressur eu japan file expir juli includ pedi exclus numer gener launchedcrestor lc ex fx crestor expir june estab canada pressur japan canada australia new zealandcrestor emerg xl xl lc ex fx seloken/toprol xl xl estab canada australia new zealandseloken/toprol xl emerg xl brand author gener watson market sandoz threatatacand patent expir lc ex fx atacand right licens cheplapharm estab canada australia new zealandatacand emerg antagonisttenormin lc ex fx tenormin estab canada australia new zealandtenormin emerg beta blocker cowen
compani data cowen compani estim
 lc ex fx zestril estab canada australia new zealandzestril emerg lc ex fx plendil estab canada australia new zealandplendil emerg calcium channel blockeronglyza market share azn sale support komboglyz onglyza/metformin combo launch qdonglyza lc ex fx onglyza onglyza/metformin combin launch bidonglyza estab canada australia new zealandonglyza emerg dpp-iv inhib savor-timi show cv benefit hint risk headwindbrilinta market share patent term extens run patent may protect year tx approv lc ex fx brilinta retain exclus estab canada australia new zealandbrilinta emerg rec antag oral arteri thrombosi ac apprd potenti given trial failuresbydureon bcise dual chamber pen devic launch share lc ex fx bydureon estab canada australia new zealandbydureon emerg stake acquir daili patent litig settlement allow teva launch gener lc ex fx byetta launch impact limit thu farbyetta estab canada australia new zealandbyetta emerg stake acquir saxa/dapa approv launch focu forxigaforxiga lc ex fx forxiga launch estab emerg chinaforxiga inhibitor diabet declar cv data lc ex fx other estab canada australia new zealandoth emerg cowen
compani data cowen compani estim
ckd/chf zirconium silic absorb approv eu launch japan file pat exp via zs free fatti acid composit approv japan file omthera acquir build suppli prior dual agonist phase ii modul phase lcat phase coronari arteri diseas phase cv diseas phase market share stabl volum price pressuresymbicort lc ex fx symbicort gener file adavir gener pressuresymbicort estab canada australia new zealandsymbicort emerg nebul infant patent rule invalid gener launchedpulmicort lc ex fx pulmicort estab canada australia new zealandpulmicort emerg chinapulmicort lc ex fx rhinocort estab emerg steroidtudorza/eklira circassia lc ex fx tudorza/eklira estab emerg lama via almiral resp acq milestonesdaliresp/daxa right acquir actavi lc ex fx daliresp/daxa right acquir estab emerg inhibitor copd via actavi file june royalti aznduaklir lc ex fx duaklir estab emerg bid inhal copdoth lc ex fx other estab canada australia new zealandoth emerg oxi ou cowen
compani data cowen compani estim
mab sever asthma apprd us eu japan copd trial failedbevespi laba/lama formoterol/glycopyrrol copd market file eu copd phase file /eu/japan/china asthma phase agonist asthma phase laba asthma/copd phase ii via sgrm asthma/copd phase sgrm ra/respiratori phase copd phase mab asthma atop dermat file us eu copd phase launch lc ex fx arimidex expir exclus extend estab canada australia new zealandarimidex emerg inhibitor ai breast cancercasodex expir lc ex fx casodex estab canada australia new zealandcasodex emerg anti-androgen prostat cancerzoladex lc ex fx zoladex estab canada australia new zealandzoladex emerg agonist prostat cancer gyn/fertil disord use month releas gener gener one month depotiressa expir lc ex fx iressa expir estab canada australia new zealandiressa emerg drive growthiressa posit nsclcfaslodex patent exp follow-on patent may protectfaslodex lc ex fx faslodex estab canada australia new zealandfaslodex emerg posit nsclc new line breast claim/combo inhibitor power growthlynparza approvedlynparza lc ex fx lynparza approv breast estab countrieslynparza emerg china oral parp-brca ovarian breast gastric prostat pancreat collabor cowen
compani data cowen compani estim
 tagrisso lc ex fx tagrisso eutagrisso estab japan emerg nsclc line solid tumor phase potenti countriesoth lc ex fx other estab canada australia new zealandoth emerg nolvadex tomudeximfinzi approv bladder unresect stage nsclc imfinzi lc ex fx imfinzi stage nsclc estab emerg scchn w/treme solid btki apprd mcl trial cll/sll dlbcl fl mm wm nhl via stake mab lung cancer combo phase file us eu japan inhib shorter diff thyroid us eu file nsclc phase inhibitor papillari renal cell carcinoma phase eu nda mtor serine/threonin kinas inhibitor solid tumor phase iiazd tyrosin kinas inhibitor gastric breast nsclc phase kinas oral small molecul combo ovarian solid tumor akt inhibitor breast cancer phase inhibitor combo lynparza solid tumor phase pasudotox recombin immunotoxin hairi cell leukemia approv us ir patent expir seroquel ir lc ex fx seroquel ir expir ir estab canada australia new zealandseroquel ir emerg certain market ir xr sold luy pharma ir xr launch xr lc ex fx seroquel xr patent expir may xr estab canada australia new zealandseroquel xr emerg xr expir lc ex fx zomig lc ex estab canada australia new zealandzomig emerg triptan migrainediprivan record sale diprivan lc ex fx diprivan estab canada australia new zealanddiprivan emerg cowen
compani data cowen compani estim
anesthet record sale local anesthet lc ex fx local anesthet sold aspenloc anesthet estab anesthet emerg anesthet marcain lc ex fx synagi estab canada australia new zealandsynagi emerg mab bind f-protein rsvflumist/fluenz recommend use flu seasonflumist/fluenz lc ex fx flumist/fluenz estab canada australia new zealandflumist/fluenz emerg influenza vaccin healthi patient age yearsoth lc ex fx other stab canada australia new zealandoth emerg factor prolyl hydroxylas inhibitor anemia ckd/esrd nda us china select uric acid reabsorpt inhibitor chronic kidney diseas phase mab influenza treatment phase ii track mab primari sjogren syndrom phase bispecif mab prevent nosocomi pseudomona pneumonia phase ii fast bind aureu toxin hospital-acquir pneumonia/seri aureu infect phase mab-yt passiv rsv prophylaxi phase ii track esomeprazol oa ra symptom ou divest right anti-ifn-alphar mab sle phase trial miss endpoint continu moderate/sever activ sle lupu nephriti phase ii sq lupu phase iizinforosold along small molecul anti-infect primarili commerci partnership out-licens royalti mileston licens recur cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl crestor brilinta
success pipelin product success deal patent litig patent
expir pressur uncertainti strateg direct could includ
outlook dividend
